INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
申请人:Dumas Jacques
公开号:US20120046290A1
公开(公告)日:2012-02-23
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
申请人:Miller Scott
公开号:US20080269265A1
公开(公告)日:2008-10-30
This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病,以及用于该疗法的药物组合物。
Oxalohydrazide Ligands for Copper‐Catalyzed C−O Coupling Reactions with High Turnover Numbers
作者:Ritwika Ray、John F. Hartwig
DOI:10.1002/anie.202015654
日期:2021.4.6
long‐lived copper catalysts for couplings that form the C−O bonds in biaryl ethers. These Cu‐catalyzed coupling of phenols with aryl bromides occurred with turnovers up to 8000, a value which is nearly two orders of magnitude higher than those of prior couplings to form biaryl ethers and nearly an order of magnitude higher than those of any prior copper‐catalyzed coupling of aryl bromides and chlorides
[EN] METHOD OF PREPARING SILYLATIVE-REDUCED N-HETEROCYCLIC COMPOUND USING ORGANOBORON CATALYST<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ N-HÉTÉROCYCLIQUE RÉDUIT PAR SILYLATION À L'AIDE D'UN CATALYSEUR À BASE D'ORGANOBORE
申请人:INST BASIC SCIENCE
公开号:WO2016076479A1
公开(公告)日:2016-05-19
Provided is a method of preparing a silylative-reduced N-heterocyclic compound by reducing an N-heteraromatic compound including a sp2 hybridized nitrogen atom while simultaneously introducing a silyl group into a beta-position with respect to a nitrogen atom of the N-heteroaromatic compound, using a silane compound, in the presence of an organoboron catalyst.